Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted “Breakthrough Device” designation to DUOnco^TM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the legal manufacturer.

Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans.

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, took part in the Side Event AI Action Summit, an event held on February 11, 2025 at the Grand Palais in Paris, as part of AI Action Week.

Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, publishes its consolidated sales for the full year 2024.

Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being deployed on clinical sites.

Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian® and Liflow®, Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance’s “Innovation in Medical Imaging” call for proposals. The Oncology Assistant (trade name: Liflow®) project, carried by the four Partners uses AI (artificial intelligence) to facilitate and optimize the follow-up of cancer patients. It benefits from public funding to ensure its future development.

Intrasense (FR0011179886 - ALINS), medical imaging software expert and developer of Myrian® and Liflow®, is proud to announce that the Myrian® 2.13 platform has obtained the CE marking under MDR1, including a major new version of the prostate AI developed by Guerbet, Veolity® LungCAD AI developed by MeVis Medical Solutions AG and Icobrain™ AI developed by Icometrix.